JP6470879B1 - 抗炎症剤、抗炎症用医薬組成物、抗炎症用食品組成物 - Google Patents
抗炎症剤、抗炎症用医薬組成物、抗炎症用食品組成物 Download PDFInfo
- Publication number
- JP6470879B1 JP6470879B1 JP2018543736A JP2018543736A JP6470879B1 JP 6470879 B1 JP6470879 B1 JP 6470879B1 JP 2018543736 A JP2018543736 A JP 2018543736A JP 2018543736 A JP2018543736 A JP 2018543736A JP 6470879 B1 JP6470879 B1 JP 6470879B1
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory
- inflammation
- inflammatory agent
- present
- protein catabolism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002260 anti-inflammatory agent Substances 0.000 title claims abstract description 62
- 229940121363 anti-inflammatory agent Drugs 0.000 title claims abstract description 62
- 235000013305 food Nutrition 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 21
- 230000015556 catabolic process Effects 0.000 claims abstract description 72
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 71
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 71
- 206010061218 Inflammation Diseases 0.000 claims abstract description 69
- 230000004054 inflammatory process Effects 0.000 claims abstract description 69
- 150000004667 medium chain fatty acids Chemical class 0.000 claims abstract description 64
- 208000002720 Malnutrition Diseases 0.000 claims abstract description 31
- 235000000112 undernutrition Nutrition 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 210000004556 brain Anatomy 0.000 claims description 17
- 230000009545 invasion Effects 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 12
- 230000002265 prevention Effects 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 description 67
- 230000037396 body weight Effects 0.000 description 26
- 235000014113 dietary fatty acids Nutrition 0.000 description 20
- 229930195729 fatty acid Natural products 0.000 description 20
- 239000000194 fatty acid Substances 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 150000004665 fatty acids Chemical class 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 235000012054 meals Nutrition 0.000 description 12
- 230000007423 decrease Effects 0.000 description 10
- 210000001320 hippocampus Anatomy 0.000 description 10
- 239000000470 constituent Substances 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 8
- 108010071690 Prealbumin Proteins 0.000 description 8
- 102000009190 Transthyretin Human genes 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- -1 acyl glycerol Chemical compound 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 108010074051 C-Reactive Protein Proteins 0.000 description 6
- 102100032752 C-reactive protein Human genes 0.000 description 6
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 6
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000003914 Cholinesterases Human genes 0.000 description 4
- 108090000322 Cholinesterases Proteins 0.000 description 4
- 208000030814 Eating disease Diseases 0.000 description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 description 4
- 108700028909 Serum Amyloid A Proteins 0.000 description 4
- 102000054727 Serum Amyloid A Human genes 0.000 description 4
- 229940048961 cholinesterase Drugs 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 235000014632 disordered eating Nutrition 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 150000004668 long chain fatty acids Chemical class 0.000 description 4
- 235000000824 malnutrition Nutrition 0.000 description 4
- 230000001071 malnutrition Effects 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 235000003715 nutritional status Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 235000013310 margarine Nutrition 0.000 description 2
- 239000003264 margarine Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 239000003346 palm kernel oil Substances 0.000 description 2
- 235000019865 palm kernel oil Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- HABLENUWIZGESP-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O HABLENUWIZGESP-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- ACXGEQOZKSSXKV-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCC(O)=O ACXGEQOZKSSXKV-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 125000005472 straight-chain saturated fatty acid group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明の抗炎症剤は、中鎖脂肪酸を有効成分として含む。以下、「中鎖脂肪酸」を「MCFA」ともいう。「中鎖脂肪酸を有効成分として含む」とは、本発明の抗炎症剤中に含まれる生理活性物質として、中鎖脂肪酸が少なくとも含まれることを意味する。
MCFAは、炭素数6〜12の直鎖飽和脂肪酸であり、通常の食品等(例えば、食用油脂や乳製品等)に含まれる油脂成分である。より安全性の高い抗炎症剤が得られやすいという観点から、MCFAは、炭素数8〜12の直鎖飽和脂肪酸であることが好ましく、炭素数8及び/又は10の直鎖飽和脂肪酸であることがより好ましい。具体的なMCFAとしては、カプロン酸(n−ヘキサン酸)、カプリル酸(n−オクタン酸)、カプリン酸(n−デカン酸)、ラウリン酸が挙げられる。
本発明の抗炎症剤は、炎症、特に、タンパク異化亢進(例えば、低栄養や摂食障害時等に生じるタンパク異化亢進、侵襲によるタンパク異化亢進)時の炎症の予防又は治療に用いることができる。本発明において「予防」とは、例えば、炎症の発症の抑制又は遅延等を意味し、「治療」とは、例えば、炎症の進行の遅延、並びに、症状の緩和、軽減、改善及び治癒等を意味する。
本発明の抗炎症剤は、抗炎症用医薬組成物の製造のために適用できる。本発明の抗炎症剤を含む抗炎症用医薬組成物(以下、「本発明の医薬組成物」ともいう。)は、副作用の懸念の少なく、継続投与に適した医薬品として好ましく利用できる。
本発明の抗炎症剤は、抗炎症用食品組成物の製造のために適用できる。本発明の抗炎症剤の有効成分であるMCFAは、副作用の懸念が少ないだけではなく、食品の風味や嗜好性を損ないにくい。そのため、本発明の抗炎症剤を含む抗炎症用食品組成物(以下、「本発明の食品組成物」ともいう。)は摂食しやすい食品として好ましく利用できる。
AIN−93Gに準拠し、脂質として長鎖脂肪酸油(以下、「LCT」ともいう。)、又は、MCT及びLCTを含む、低栄養食(PEM食)を2種類作製した。以下、LCTを含むPEM食を「PEM−LCT」ともいい、MCT及びLCTを含むPEM食を「PEM−MCT」ともいう。また、対照群用の普通食(AIN−93G)も作製した。PEM食及び普通食の配合を表1(表中の数値の単位:質量部)に示す。各試験食は、ペレット状に調製した。LCTは、AIN−93G等の標準的な飼料組成に含まれる油脂である。
以下に示す方法で、タンパク異化亢進時の炎症(低栄養によるタンパク異化亢進時の炎症及び侵襲によるタンパク異化亢進時の炎症)が生じているマウスを準備した。まず、栄養状態が不良である低栄養(PEM)のモデルマウスを作製した。さらに、該マウスに対して、侵襲の処置としてリポポリサッカライド(以下、「LPS」ともいう。)を腹腔内投与し、目的とするマウスを得た。なお、LPSは、炎症を惹起するグラム陰性細菌細胞壁外膜由来の毒素である。LPSの投与により、マウスにおいて、タンパク異化亢進状態が誘導され、全身の様々な臓器だけでなく、脳海馬等に炎症が惹起されることが知られる。
各試験群から採取した脳海馬において、3種類の炎症マーカー(IL−1β、iNOS、及びTNF−α)のmRNA発現量を測定した。これらの炎症マーカーのmRNA発現量を測定することで、脳海馬の炎症の程度を特定できる。
各試験群から採取した脳海馬から、RNA抽出キット(Sepasol RNA I、ナカライテスク株式会社)を用いて、全RNAを単離した。次いで、PCR装置(商品名「PC818」、ASTEC社製)を用いて、表2に示す試薬及びプライマーを用いて、mRNAの発現量を測定した。
各試験群における炎症マーカー(IL−1β、iNOS、及びTNF−α)のmRNA発現量を、表3及び図1に示す。なお、mRNAの発現量は、各試験群における発現量の数値を、普通食(対照)におけるmRNAの発現量の平均値を100とした場合の、相対値の平均値±標準誤差(%)として特定した。なお、試行間の有意差検定には、Tukey法を用いた。
Claims (4)
- 中鎖脂肪酸を有効成分として含む、低栄養によるタンパク異化亢進時の脳内の炎症の予防又は治療のための、抗炎症剤。
- 前記中鎖脂肪酸として、中鎖脂肪酸トリグリセリドを含む、請求項1に記載の抗炎症剤。
- 請求項1又は2に記載の抗炎症剤を含む、抗炎症用医薬組成物。
- 請求項1から3のいずれかに記載の抗炎症剤を含む、抗炎症用食品組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017043704 | 2017-03-08 | ||
JP2017043704 | 2017-03-08 | ||
PCT/JP2018/004727 WO2018163716A1 (ja) | 2017-03-08 | 2018-02-09 | 抗炎症剤、抗炎症用医薬組成物、抗炎症用食品組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6470879B1 true JP6470879B1 (ja) | 2019-02-13 |
JPWO2018163716A1 JPWO2018163716A1 (ja) | 2019-03-14 |
Family
ID=63447685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018543736A Active JP6470879B1 (ja) | 2017-03-08 | 2018-02-09 | 抗炎症剤、抗炎症用医薬組成物、抗炎症用食品組成物 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP6470879B1 (ja) |
CN (1) | CN110290785A (ja) |
WO (1) | WO2018163716A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004043337A (ja) * | 2002-07-10 | 2004-02-12 | Nisshin Oillio Ltd | 血中中性脂肪濃度調整剤 |
WO2016033699A1 (en) * | 2014-09-05 | 2016-03-10 | Rsem, Limited Partnership | Compositions and methods for treating and preventing inflammation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL148736A0 (en) * | 2002-03-18 | 2002-09-12 | Pharmos Corp | Dexanabinol and dexanabinol analogs which regulate inflammation related genes |
PT2374452T (pt) * | 2008-12-05 | 2019-10-31 | Ajinomoto Kk | Composição de nutrientes |
-
2018
- 2018-02-09 CN CN201880011488.4A patent/CN110290785A/zh active Pending
- 2018-02-09 JP JP2018543736A patent/JP6470879B1/ja active Active
- 2018-02-09 WO PCT/JP2018/004727 patent/WO2018163716A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004043337A (ja) * | 2002-07-10 | 2004-02-12 | Nisshin Oillio Ltd | 血中中性脂肪濃度調整剤 |
WO2016033699A1 (en) * | 2014-09-05 | 2016-03-10 | Rsem, Limited Partnership | Compositions and methods for treating and preventing inflammation |
Non-Patent Citations (1)
Title |
---|
河野寛,藤井秀樹: "手術侵襲と脂肪", JOURNAL OF JAPANESE SOCIETY FOR MEDICAL USE OF FUNCTIONAL FOODS, vol. 8, no. 4, JPN6018009898, October 2014 (2014-10-01), pages 264 - 270, ISSN: 0003877513 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018163716A1 (ja) | 2018-09-13 |
CN110290785A (zh) | 2019-09-27 |
JPWO2018163716A1 (ja) | 2019-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1307108B1 (en) | Oil/fat composition | |
EP1430783B1 (en) | Oil/fat composition | |
US20210260015A1 (en) | Composition for inhibiting fat accumulation | |
WO2013039210A1 (ja) | Gip上昇抑制剤 | |
EP2671579B1 (en) | Fat and oil composition for promoting insulin secretion | |
EP2554166B1 (en) | Oil and fat composition for the treatment of diabetes | |
JP6470879B1 (ja) | 抗炎症剤、抗炎症用医薬組成物、抗炎症用食品組成物 | |
JP2004075653A (ja) | 体脂肪分解促進剤および飲食物 | |
JP5702292B2 (ja) | パーキンソン病患者の内臓脂肪減少抑制剤 | |
KR100684641B1 (ko) | 유지 조성물, 이를 함유하는 식품 및 건강보조식품 | |
JP2004210652A (ja) | 糖尿病患者における脂質代謝改善剤 | |
JP7245399B2 (ja) | 血中デカン酸濃度の上昇方法、血中デカン酸濃度上昇剤、医薬組成物、食品組成物 | |
EP3622951B1 (en) | Agent for raising total ketone concentration, oil and fat composition, pharmaceutical composition, and food product composition | |
JP2007045789A (ja) | 食後高インスリン血症改善剤 | |
JP2023173641A (ja) | 内臓脂肪低減剤およびその用途 | |
JP2022150493A (ja) | 血中中鎖脂肪酸濃度の上昇方法、血中中鎖脂肪酸濃度上昇剤、医薬組成物、食品組成物 | |
JP2021016375A (ja) | 有酸素性運動機能向上剤、有酸素性運動機能向上用食品組成物、有酸素性運動機能向上用医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180817 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180817 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20180817 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20180904 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20181101 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190108 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190118 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6470879 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |